Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Historical Holders from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
MLYS on Nasdaq
Shares outstanding
77,392,610
Price per share
$36.29
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
79,306,949
Total reported value
$3,007,317,130
% of total 13F portfolios
0.02%
Share change
+12,998,954
Value change
+$505,416,558
Avg buy value change
+0%
Avg sell value change
-0.01%
Number of holders
191
Price from insider filings
$35.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mineralys Therapeutics, Inc. - Common Stock (MLYS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Catalys Pacific Fund, LP 14% $136,659,680 8,978,954 Catalys Pacific Fund, LP 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $118,661,710 +$22,964,484 7,796,433 +24% RA Capital Management, L.P. 04 Sep 2025
Samsara BioCapital, L.P. 8.2% -10% $96,589,073 +$9,282,511 6,346,194 +11% Srinivas Akkaraju 04 Sep 2025
Andera Partners 4.2% $42,098,155 2,765,976 Andera Partners 30 Jun 2025
ADAMS STREET PARTNERS LLC 2.3% $14,495,424 1,129,807 Adams Street Partners, LLC 31 Dec 2024
As of 30 Sep 2025, Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 191 institutional shareholders filing 13F forms. They hold 79,306,949 shares. .

Top 25 institutional shareholders own 79% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Catalys Pacific, LLC 12% 8,903,838 0% 96% $337,633,537
RA CAPITAL MANAGEMENT, L.P. 9.5% 7,323,750 +19% 3.4% $277,716,600
SAMSARA BIOCAPITAL, LLC 8.1% 6,263,151 +10% 31% $237,498,686
BlackRock, Inc. 4.7% 3,671,614 +19% 0% $139,227,602
VANGUARD GROUP INC 3.9% 3,018,999 +30% 0% $114,480,442
Caligan Partners LP 3.6% 2,772,654 +37% 15% $105,139,040
Capital International Investors 3.1% 2,393,396 -17% 0.01% $90,757,576
SUVRETTA CAPITAL MANAGEMENT, LLC 2.8% 2,132,133 +22% 2.5% $80,850,483
SR One Capital Management, LP 2.7% 2,113,933 -32% 12% $80,160,339
FMR LLC 2.7% 2,071,255 +579% 0% $78,541,989
CITADEL ADVISORS LLC 2.7% 2,067,227 +14274% 0.06% $78,389,248
FRANKLIN RESOURCES INC 2.3% 1,809,768 +0.34% 0.02% $68,626,402
Point72 Asset Management, L.P. 2.3% 1,799,628 0.15% $68,241,889
Laurion Capital Management LP 2.2% 1,720,445 -2.4% 8.9% $65,239,274
FARALLON CAPITAL MANAGEMENT LLC 2.2% 1,673,053 0.36% $63,442,170
Integral Health Asset Management, LLC 1.9% 1,500,000 -44% 4.1% $56,880,000
ORBIMED ADVISORS LLC 1.9% 1,469,494 +93% 1.3% $55,723,212
MORGAN STANLEY 1.8% 1,376,997 +134% 0% $52,215,755
STATE STREET CORP 1.7% 1,303,023 -9.7% 0% $49,410,632
Holocene Advisors, LP 1.6% 1,205,377 0.11% $45,707,896
GEODE CAPITAL MANAGEMENT, LLC 1.5% 1,123,411 +18% 0% $42,608,185
Polar Capital Holdings Plc 1.4% 1,058,776 0.19% $40,148,786
BOOTHBAY FUND MANAGEMENT, LLC 1.2% 942,626 +15% 0.9% $35,744,378
Pictet Asset Management Holding SA 1.2% 929,169 -27% 0.03% $35,234,088
ALLIANCEBERNSTEIN L.P. 1.1% 882,415 +3160% 0.01% $33,461,177

Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 232,154 $8,425,320 +$4,746,000 3,629.15% 5
2025 Q3 79,306,949 $3,007,317,130 +$505,416,558 3,792% 191
2025 Q2 65,687,280 $888,767,559 +$52,640,118 1,353% 164
2025 Q1 61,178,854 $971,385,321 +$245,430,094 1,588% 148
2024 Q4 46,486,259 $572,248,967 +$24,847,746 1,231% 108
2024 Q3 44,382,325 $540,052,163 +$2,379,004 1,211% 105
2024 Q2 44,151,028 $516,569,184 +$24,151,309 1,170% 93
2024 Q1 41,871,642 $540,562,555 +$94,145,212 1,291% 91
2023 Q4 20,500 $176,300 -$104,920 860% 1
2023 Q3 26,512,068 $252,135,312 -$9,252,095 951% 77
2023 Q2 25,186,898 $429,225,054 +$10,759,776 1,705% 68
2023 Q1 24,614,198 $385,430,964 +$385,430,964 1,566% 66